Abstract: Disclosed are adsorption complexes that include 1-methylcyclopropene (1-MCP) and a metal coordination polymer network (MCPN), wherein the MCPN is a porous material, and the 1-MCP is adsorbed into the MCPN. Also disclosed are kits for containing 1-MCP that include the adsorption complex in a 1-MCP-impermeable package. Also disclosed are methods of releasing 1-methylcyclopropene (1-MCP) from the kit that include the application of aqueous fluids, heat, and/or pressure.

Abstract: Processes for recovering paraxylene from at least two feedstreams containing xylene isomers. The process includes directing to a paraxylene recovery zone comprising at least one crystallization zone, a paraxylene-lean feedstream having a paraxylene to total xylene isomer ratio of 0.50 or less, and also directing to the paraxylene recovery zone, a paraxylene-rich feedstream having a paraxylene to total xylene isomer ratio of greater than 0.50. A paraxylene-containing product stream is recovered from the paraxylene recovery zone having a paraxylene to total xylene isomer ratio greater than that of the paraxylene-rich feedstream. The process provides improvements in paraxylene recovery efficiency and/or cost effectiveness.

Abstract: Novel selective synthesis route to introduce primary alkyl groups on aromatic compounds is disclosed. The synthesis route is based on electrophilic aromatic substitutions of thionium ion species that are generated in-situ from aldehydes and thiols, affording benzyl sulfide that can be reduced with triethylsilane.

Abstract: The present invention relates to a method for preparing a polyinsaturated perfluorinated compound B from a polyinsaturated perhalogenated compound D having the formula CnX2(n?m+1), in which X is independently selected from one of the halogens, F, Cl, Br or I, provided at least one X is not fluorine; n is the number of carbon atoms and is at least higher than or equal to 4, m is the number of double carbon-carbon bonds and is higher than or equal to 2, wherein the method comprises a step in which compound D is fluorinated in the presence of a fluorinating agent of general formula AFp, in which A is hydrogen, an alkali metal or an alkaline earth metal, and p is 1 or 2, and in the presence of an aprotic organic polar solvent; the method being carried out with a molar ratio of AFp to compound D of less than 1.45*2(n?m+1).

Abstract: The present disclosure provides various manufacturing processes for the production of 2,3,3,3-tetrafluoropropene (HFO-1234yf or 1234yf). Such methods may allow for the improved yields, more economical processes, and waste reduction in the production of 1234yf and subsequent processes.

Abstract: A process is provided comprising contacting and reacting the compound CF3CF2CHXCl, wherein X is H or Cl, or the compound CF3CF?CXCl, wherein X is H or Cl, with hydrogen in the presence of a catalyst consisting essentially of Cu, Ru, Cu—Pd, Ni—Cu, and Ni—Pd, to obtain as a result thereof reaction product comprising hydrofluoropropenes or intermediates convertible to said hydrofluoropropenes, notably CF3CF?CH2 and CF3CH?CHF.

Abstract: The present invention provides a process for the preparation of 1,4-butanediol and tetrahydrofuran said process comprising contacting furan with hydrogen and water in the presence of a supported catalytic composition comprising at least one first metal selected from those in groups 8 to 10 of the periodic table and a further metal selected from manganese, molybdenum, niobium and tungsten.

Abstract: The invention pertains to the use of a solvent that comprises a Lewis donor compound that is selected from the group made up of unsaturated fatty acids that have between 12 and 18 carbon atoms, phosphate esters that have between 12 and 30 carbon atoms, and mixtures thereof to separate the impurities from a feedstock that contains ethanol, acetaldehyde, and impurities.

Abstract: A method for producing hemp oil, comprising decarboxylation of CBDA in hemp oil; short-path evaporation of CBD from the decarboxylated hemp oil to produce CBD oil; selective THC to CBN conversion performed on the decarboxylated hemp oil.

Abstract: The production of solvents for applications such as heat transfer, cleaning, and degreasing, for example. In particular, the production of solvents derived from 1-chloro-3,3,3-trifluoro-propene, such as chloro and/or fluoro substituted alkanes and chloro and/or fluoro substituted trifluoropropenyl ethers.

Abstract: The present invention relates to a composition for preventing or reducing microbial growth, particularly the growth of dermatophytic fungi, and/or aciduric and acidogenic gram-positive bacteria. More particularly, it relates to the use of trans-3,5,4?-trihydroxybibenzyl, also known as dihydro-resveratrol, or its dihydrostilbene derivatives and/or chemical variants as an anti-microbial agent. The present invention further relates to the management of dermatophytosis often caused by dermatophytic fungi and the management of dental caries often mediated by aciduric and acidogenic gram-positive Streptococci. The present invention therefore has applications in preventing, alleviating and/or treating dermatophytosis and dental caries.

Abstract: The present invention relates to a compound having the formula (I), as well as a method for preparing such a compound, a cosmetic or pharmaceutic composition containing such a compound, and the use thereof as a depigmenting, lightening, bleaching or whitening agent and for treating pigmentation disorders, notably by topical application on the skin.

Abstract: Disclosed is an industrial method for efficient production of an ?,?-difluoroaldehyde compound, which includes reaction of an ?,?-difluoroacetate with hydrogen gas (H2) in the presence of a ruthenium catalyst and a base. By the adoption of specific reaction conditions (catalyst, base, pressure etc.), it is possible to produce the target ?,?-difluoroaldehyde compound with a high conversion rate and high selectivity.

Abstract: The present invention relates generally to processes for producing aldehydes wherein an olefinic compound, carbon monoxide, and hydrogen are reacted in the presence of a solubilized rhodium-phosphorous complex. In one embodiment, the process comprises (a) receiving a vaporized aldehyde product stream downstream from a hydroformylation reactor, the vaporized aldehyde product stream comprising aldehydes, phosphorous ligand, and aldehyde condensation by-products; (b) contacting the vaporized aldehyde product stream with a partial condenser so as to condense the phosphorous ligand and the by-products, wherein up to 10 weight percent of the vaporized stream is condensed; (c) removing the condensed phosphorous ligand and the condensed by-products from the liquid condensation stream using a refining column; and (d) further processing the vaporized aldehydes from the separate refining column.

Abstract: Methods of synthesizing phenanthrenequinone, 9-hydroxyfluorene-9-5 carboxylic acid (“HFCA”), methyl-9-hydroxyfluorene-carboxylate (“HFCA methyl ester”) and methyl-2-chloro-9-hydroxyfluorenecarboxylate, (“Chlorflurenol”) starting from preferred embodiment are disclosed. Several reaction products of phenanthrene are useful in industry, and are valuable plant growth regulators.

Abstract: An integrated process for the production of one or more acetylene derivatives is provided. The integrated process includes a) partially oxidizing a hydrocarbon feedstock to produce a partial oxidation mixture comprising H2, CO, and acetylene, b) providing the H2 and CO of the partial oxidation mixture to a collocated methanol production process to produce a methanol-containing effluent; c) providing the methanol-containing effluent to a collocated carbonylation process to produce an acetic acid-containing effluent; and d) providing the acetylene of the partial oxidation mixture and the acetic acid-containing effluent to one or more of the collocated acetylene-derivative processes following: i) a vinyl acetate monomer production process; ii) an oxidation unit for the production of formaldehyde from the methanol-containing effluent; iii) a vinyl chloride monomer production process, and/or iv) a 1,4-butanediol production process.

Abstract: This disclosure relates to methods for producing purified aromatic esters useful as plasticizers, to the purified aromatic esters, and to polymer compositions containing the purified esters. The purified aromatic esters can be produced by esterifying carboxylic acid with methyl or ethyl alcohol, separating the resulting methyl or ethyl esters from the carboxylic acid and any byproduct impurities, and then transesterifying the methyl or ethyl esters with C4 to C14 alcohol to produce the purified aromatic esters. Additionally, precipitation, filtration, and wash steps can be employed to purify the carboxylic acid, the methyl or ethyl alcohol, and/or the aromatic esters.

Abstract: A carbonate ester purification apparatus including a first distillation column in which an alcohol and a first solution containing a carbonate ester and formaldehyde, or a first solution containing a carbonate ester, formaldehyde and an alcohol is supplied to obtain a distillate containing the formaldehyde and the alcohol from a column top part while obtaining a carbonate ester solution with a lower content of formaldehyde than in the first solution from a column bottom part, a reactor having a catalyst for producing an acetal and/or a hemiacetal by reacting the formaldehyde to the alcohol and a reflux part refluxing a fluid containing the acetal and/or the hemiacetal to the first distillation column.

Abstract: Provided is a carbonate ester purification apparatus including a treatment part for mixing a first solution containing a carbonate ester and an acidic substance with an alcohol solution of a metal alcoholate to obtain a mixed solution containing a reaction product of the acidic substance and the metal alcoholate, a separation part for removing a metal salt contained in the reaction product from the mixed solution to obtain a second solution, and a distillation part for removing a component from the second solution, the component different in boiling point from the carbonate ester to obtain a carbonate ester solution, wherein a content of the metal alcoholate in the alcohol solution is 5 to 18 mass %.

Abstract: Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.

Abstract: Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.

Abstract: Cyclic vinylogous amides of Formula I are disclosed The compounds are useful for treating diseases that arise from inappropriate activity of proteins containing an acetyl-lysine. The compositions comprise a genus of cyclic vinylogous amides that are inhibitors of bromodomain.

Abstract: A method of producing an organic compound, which contains a step of performing a deodorization step using a flow reaction in a flow passage to remove, from a reaction liquid, a malodorous material generated or remaining in a reaction step, wherein the organic compound is an industrially useful compound.

Abstract: Provided are: a compound, a thickening/stabilizing agent including the compound, a thickened/stabilized composition including the thickening/stabilizing agent and a fluid organic substance, and a method for producing the thickened/stabilized composition, where the compound effectively thickens the fluid organic substance to a desired viscosity and effectively uniformly stabilizes the formulation of the composition containing the fluid organic substance via thickening of the fluid organic substance. The thickening/stabilizing agent according to the present invention includes a compound represented by Formula (1): (R2—HNOC)4-n—R1—(CONH—R3)n??(1) where R1 is a group resulting from removing four hydrogen atoms from the structural formula of butane; R2 and R3 are different from each other and are aliphatic hydrocarbon groups each containing 4 or more carbon atoms; and n is an integer of 1 to 3.

Abstract: The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns compounds (e.g., compounds according to any of Formulas (I)-(XIII) and in particular Formula (X), and Compounds (1)-(236) of Table 1) that are useful in treatment of a variety of diseases and conditions.

Abstract: The present invention concerns new forms of crystalline minocycline base. In particular, two new crystalline polymorphic forms, designated Form IV and Form V of minocycline base are provided. These are characterized by XRD, FTIR and TGA. Processes for preparing the new polymorphic forms and their use in pharmaceutical compositions are also provided. Form IV and form V are prepared by dissolving and/or suspending minocycline base in an organic solvent followed by crystallization.

Abstract: Described are new forms of crystalline minocycline base. In particular, two new crystalline polymorphic forms, designated Form IV and Form V of minocycline base are provided. These are characterized by XRD, FTIR and TGA. Processes for preparing the new polymorphic forms and their use in pharmaceutical compositions are also provided. Form IV and Form V are prepared by dissolving and/or suspending minocycline base in an organic solvent followed by crystallization.

Abstract: This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic

Abstract: Processes for separating carbon dioxide from CO2-containing gases and an apparatus for providing carbon dioxide for the synthesis of urea.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing CNS disorders containing a sulfamate derivative compound and/or pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a method for treatment or prevention CNS disorders comprising administering a sulfamate derivative compound in a pharmaceutically effective amount to a subject in need of treatment or prevention of CNS disorders.

Abstract: Provided herein are various methods for forming alkylaromatic sulfonate compositions and blended alkylaromatic sulfonate compositions, and such compositions themselves. The methods of various embodiments include obtaining a C8-C30 hydrocarbon mixture, optionally treating the mixture to concentrate the mixture in sulfonatable aromatics, and sulfonating the mixture to form the alkylaromatic sulfonates. The mixture or treated mixture may be blended with linear alkyl benzene (LAB) compositions and sulfonated, and/or the alkylaryl sulfonates may be blended with linear alkylbenzene sulfonate (LAS) compositions, to form the blended alkylaromatic sulfonates of some embodiments. These compositions and processes for making them may be tailored to serve a variety of end uses, such as detergents in cleaning solutions or for enhanced oil recovery operations, and/or as low foaming and/or hydrotropic additives in detergent formulations, and the like.

Abstract: Provided herein are various methods for forming alkylaromatic sulfonate compositions and blended alkylaromatic sulfonate compositions, and such compositions themselves. The methods of various embodiments include obtaining a C8-C30 hydrocarbon mixture, optionally treating the mixture to concentrate the mixture in sulfonatable aromatics, and sulfonating the mixture to form the alkylaromatic sulfonates. The mixture or treated mixture may be blended with linear alkyl benzene (LAB) compositions and sulfonated, and/or the alkylaryl sulfonates may be blended with linear alkylbenzene sulfonate (LAS) compositions, to form the blended alkylaromatic sulfonates of some embodiments. These compositions and processes for making them may be tailored to serve a variety of end uses, such as detergents in cleaning solutions or for enhanced oil recovery operations, and/or as low foaming and/or hydrotropic additives in detergent formulations, and the like.

Abstract: The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

Abstract: UV-absorbing compounds are provided that have at least one reactive hydrogen. These compounds have structures: wherein the generic notations have meanings as described herein. Also provided are formulations comprising a UV-absorbing compounds.

Abstract: A Hydrocarbyl Carboxybetaine represented by Formula (1) is provided: wherein, n1?0 and n2>0, A is a C1-C20 alkyl group when n1>0, and A is a single bond when n1=0.

Abstract: A compound which is a thienolate of formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R1, R3, Ring A1, n and Ring A2 are as defined herein, are found to be useful in inhibiting metallo-beta-lactamase and therefore in potentiating the activity of beta lactamase antibiotics. The compound can be used alone or in combination with a rhodanine of formula (II) or a pharmaceutically acceptable salt thereof: (II) wherein R3, Ring A1, n, Ring A2, L and Ring B are as defined herein. Treatment or prevention of bacterial infection in combination with beta-lactam antibiotic agents is also provided.

Abstract: The present invention provides a colored curable resin composition that exhibits good heat resistance and durability in a sputtering process, a cured film, a color filter, a method for manufacturing a color filter, a solid-state image device, an image display device, a compound, and a cation. The colored curable resin composition contains a colorant represented by Formula (1), Formula (2), or Formula (3), a resin, a polymerizable compound, and a polymerization initiator. In Formula (1), R101 and R102 each independently represent a hydrogen atom or a substituent, R103 to R106 each independently represent a hydrogen atom, an alkyl group, an aryl group, or a heteroaryl group, R107 to R111 each independently represent a hydrogen atom or a substituent, n1 to n4 each independently represent an integer of 0 to 4, n5 represents an integer of 0 to 6, X represents an anion or is not present, and at least one of R101, . . .

Abstract: This invention provides compound having a structure of Formulas: Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provide.

Abstract: A compound having a SF4 group on a pyridine ring is provided. Specifically, the compound is represented by the general formula (c): wherein k is 1 or 2; X is a hydrogen atom or a halogen atom; R1 is a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group having 1 to 18 carbon atoms, a substituted or unsubstituted aryl group having 6 to 30 carbon atoms, or a nitro group; and R2 is a substituted or unsubstituted alkyl group having 1 to 18 carbon atoms or a substituted or unsubstituted aryl group having 6 to 30 carbon atoms.

Abstract: Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.

Abstract: The present invention relates to arylcyclohexyl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

Abstract: Pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5HT2A receptor. Formula (Ia). Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.

Abstract: Provided is a compound of formula (I), in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.

Abstract: The present invention relates to a process for the preparation of carbamoylamino pyrazole derivatives using diacetoxyiodobenzene (PhI(OAc)2) in combination with a non-nucleophilic base.

Abstract: Salts of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium, method of preparation thereof and use in the treatment of cardiovascular disease.

Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opioid receptor and more particularly to piperazine compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: Novel crystalline forms of lesinurad and its sodium salt, processes for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transporter 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.

Abstract: The present invention provides processes for the preparation of Lesinurad (1), as well as intermediates useful in the preparation thereof. In particular, the processes of the invention utilize novel intermediate compounds of Formulas (3) and (11), which provide improvements over the known processes for the preparation of Lesinurad (1).

Abstract: The present invention provides methods respectively for producing a 2,4,6-tris(2-hydroxy-3-methyl-4-alkoxyphenyl)-1,3,5-triazine compound and 2,4,6-tris(2,4-dihydroxy-3-methylphenyl)-1,3,5-triazine, both of which are improved in yield and quality. The methods according to the present invention are characterized in that a reaction of 2,4,6-tris(2,4-dihydroxy-3-methylphenyl)-1,3,5-triazine with an alkylating agent is carried out using a base in the presence of an alcohol or water, and are also characterized in that an ester compound is used as an additive in a reaction of cyanuric chloride with 2-methylresorcinol.

Abstract: The present invention concerns compounds of formula (I): their process of preparation and compositions thereof. The present invention also concerns their use as diagnostic agent in PET imaging.